PharmaTimes digs in-depth into the findings from GHTC's report Saving lives and creating impact, which demonstrates that US government investment in global health R&D has driven the development of lifesaving technologies while also providing benefits to the US domestic economy.
In its May/June issue, the Fogarty International Center Global Health Matters newsletter interviews Mary Wooley, CEO of GHTC member Research!America, who discusses GHTC's advocacy work to promote US investment in global health R&D.
In its May/June issue, the Fogarty International Center Global Health Matters newsletter cites GHTC's report Saving lives and creating impact, which found that the US government contributed to 24 of the 45 new global health products developed between 2000 and 2010.
Regulatory Affairs Professionals Society (RAPS) explores the US Food and Drug Administration's (FDA) involvement in global health R&D, citing findings from GHTC's report Saving lives and creating impact, which notes that the FDA's approval of products intended for non-US markets can help facilitate product approval and introduction in low- and middle-income countries.